TCM
OPNT

Tradewinds Capital Management’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

Tradewinds Capital Management’s Portfolio OPNT Stock Details OPNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,500
Closed -$57K – 738
2017
Q4 		$57K Buy
+2,500
New +$80.1K 0.03% 191

Other funds holding OPNT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $20.1B AUM 30.42% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IWM
IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return

Tradewinds Capital Management's OPNT Position: Q1 2018 in Review

Tradewinds Capital Management sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q1 2018, closing a stake of 2,500 shares — an estimated $57K sold.

Tradewinds Capital Management first reported a position in OPNT in Q4 2017 and held it in 1 quarter. The position peaked at $57K in Q4 2017. 14 funds tracked by Wall St. Rank hold OPNT as of Q1 2018.

  • Tradewinds Capital Management reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Tradewinds Capital Management sold 2,500 Opiant Pharmaceuticals, Inc. Common Stock shares in Q1 2018, an estimated $57K.
  • Tradewinds Capital Management first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 1 quarter.
  • Tradewinds Capital Management's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $57K in Q4 2017.
  • 14 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q1 2018.

Based on Tradewinds Capital Management's 13F filing for Q1 2018, filed 2 May 2018.